Introducing Nubytide from Cenna Biosciences: a potential disease-modifying peptide that offers prevention and treatment for Alzheimer’s disease by using a unique mechanism to inhibit the production of Aß.

IND Filing 2024

Proof of Concept 2026-27

About Nubytide

  • Large, growing market - $3.5B+ with 6M US patients

  • Differentiated technology - disease modifying

  • 12 months from funding to first enrolled patient

  • Affordable, easy to administer

Strong IP position

  • 8 issued US patents

  • 10 issued international patents

Nubytide reduces Aß, markers of inflammation and Tau pathology

Nubytide Mission and Vision


Disease Modifying

Better Alternative

Reduces Aß Markers

Mission: Make Nubytide available to every patient in the world suffering from Alzheimer's Disease.

Mission: Nubytide is the proactive therapy to delay or stop the onset of the disease to anyone over the age of 65.

Vision: Alzheimer Disease drugs today are monoclonal antibodies which come with higher costs, are harder to administer and are less safe.

Vision: Why Nubytide? Nubytide is a peptide drug which reduces Aß, markers of inflammation and Tau pathology.

Alzheimer's Disease

Alzheimer's Disease is a growing global epidemic

Global Market

  • Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias.

  • According to the United Nations, that is more than the population of Colombia.

  • If breakthroughs are not discovered, this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

  • One in three seniors dies with Alzheimer's or related dementia.

Bright Focus Foundation – Alzheimer’s Facts and Figures

U.S. Market

Investor Opportunity

Cenna is Poised to Quickly Move Nubytide Through IND to Exit Phases

Cenna Biosciences Team

Cenna has assembled a team of seasoned biopharmaceutical specialists:

Nazneen Dewji, Ph.D.
Founder, President and CEO

Christine Smith, Ph.D.

Marwan Sabbagh, MD
Acting CMO
Professor of Neurology

Archie W. Thurston, Jr.,
Pharmacology Consultant

Grace Furman, Ph.D.
D.A.B.T., Toxicology
President and CEO,

Karlene Cork, Ph.D.
Regulatory Affairs

Contact Cenna





505 Coast S Blvd, Suite 407, La Jolla, CA 92037, United States